RU2424228C2 - Ингибиторы нейротрипсина - Google Patents

Ингибиторы нейротрипсина Download PDF

Info

Publication number
RU2424228C2
RU2424228C2 RU2007139754/04A RU2007139754A RU2424228C2 RU 2424228 C2 RU2424228 C2 RU 2424228C2 RU 2007139754/04 A RU2007139754/04 A RU 2007139754/04A RU 2007139754 A RU2007139754 A RU 2007139754A RU 2424228 C2 RU2424228 C2 RU 2424228C2
Authority
RU
Russia
Prior art keywords
neurotrypsin
agrin
cleavage
mice
protein
Prior art date
Application number
RU2007139754/04A
Other languages
English (en)
Russian (ru)
Other versions
RU2007139754A (ru
Inventor
Петер ЗОНДЕРЕГГЕР (CH)
Петер ЗОНДЕРЕГГЕР
Штефан ХЕТТВЕР (CH)
Штефан ХЕТТВЕР
Марк Ф. БОЛЛИГЕР (CH)
Марк Ф. БОЛЛИГЕР
Биргит ДРАЙЕР (CH)
Биргит ДРАЙЕР
Беат КУНЦ (CH)
Беат КУНЦ
Даниель ЛЮШЕР (CH)
Даниель ЛЮШЕР
Раймонд РАЙФ (CH)
Раймонд РАЙФ
Зузанне ЗАЛЕС (CH)
Зузанне ЗАЛЕС
Original Assignee
Юниверсити Оф Цюрих
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Юниверсити Оф Цюрих filed Critical Юниверсити Оф Цюрих
Publication of RU2007139754A publication Critical patent/RU2007139754A/ru
Application granted granted Critical
Publication of RU2424228C2 publication Critical patent/RU2424228C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6427—Chymotrypsins (3.4.21.1; 3.4.21.2); Trypsin (3.4.21.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/45—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
    • C07C311/47—Y being a hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
    • C07C311/52—Y being a hetero atom
    • C07C311/64—X and Y being nitrogen atoms, e.g. N-sulfonylguanidine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/976—Trypsin; Chymotrypsin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
RU2007139754/04A 2005-03-30 2006-03-29 Ингибиторы нейротрипсина RU2424228C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05102481 2005-03-30
EP05102481.8 2005-03-30

Publications (2)

Publication Number Publication Date
RU2007139754A RU2007139754A (ru) 2009-05-10
RU2424228C2 true RU2424228C2 (ru) 2011-07-20

Family

ID=34939082

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2007139754/04A RU2424228C2 (ru) 2005-03-30 2006-03-29 Ингибиторы нейротрипсина

Country Status (15)

Country Link
US (1) US7897364B2 (https=)
EP (1) EP1868989A2 (https=)
JP (1) JP4920675B2 (https=)
KR (1) KR20070116932A (https=)
CN (1) CN101193858B (https=)
AU (1) AU2006228150B2 (https=)
BR (1) BRPI0609654A2 (https=)
CA (1) CA2600791A1 (https=)
IL (1) IL186120A (https=)
MX (1) MX2007011961A (https=)
NO (1) NO20075461L (https=)
NZ (1) NZ562796A (https=)
RU (1) RU2424228C2 (https=)
WO (1) WO2006103261A2 (https=)
ZA (1) ZA200707359B (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008074813A2 (en) * 2006-12-21 2008-06-26 Neurotune Ag Optiogenin for the treatment of neural diseases
PL1990420T3 (pl) * 2007-05-10 2011-01-31 Neurotune Ag Sposób wykrywania aktywności neurotrypsyny in vivo, zastosowanie tego sposobu i zastosowanie C-końcowego fragmentu agryny 22 kDa jako biomarkera w diagnozowaniu i monitorowaniu zaburzeń związanych z neurotrypsyną
EP2295068A1 (en) * 2009-09-04 2011-03-16 Neurotune AG Modified agrin-fragment capable of restoring muscle strength for use as a medicament
EP2635559A2 (en) 2010-11-01 2013-09-11 Neurotune AG Neurotrypsin inhibitors
WO2012059443A2 (en) 2010-11-01 2012-05-10 Neurotune Ag Novel neurotrypsin inhibitors
EP2631657A1 (en) * 2012-02-25 2013-08-28 Neurotune AG Immunoassay for the detection of the 22kDa C-terminal fragment (CAF) of agrin

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6783949B1 (en) * 1999-04-30 2004-08-31 Aventis Pharma Deutschland Gmbh Processes for determining whether a test substance contains lipases or lipase inhibitors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH692507A5 (de) * 1997-04-26 2002-07-15 Peter Prof Dr Sonderegger Neurotrypsin als aktive Verbindung in einem Medikament.
DE10247478A1 (de) * 2002-10-11 2004-06-24 Bioagency Ag Verfahren zur Bestimmung der enzymatischen Aktivität von Proteinen

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6783949B1 (en) * 1999-04-30 2004-08-31 Aventis Pharma Deutschland Gmbh Processes for determining whether a test substance contains lipases or lipase inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Tsukamoto, Takeo и др. «Halosalicylaldehyde. I. Halosalicylaldehyde as reagent for primary amines», Kennosuke Yakugaku Zasshi, 78, 706-709, 1958. Proba, К. et al. "Cloning and sequencing of the cDNA encoding human neurotrypsin", BIOCHIMICA ET BIOPHYSICA ACTA, 1998 (1396), p.143-147. Gschwend, T.P. et al. "Neurotrypsin, a novel multidomain serine protease expressed in the nervous system", MOLECULAR AND CELLULAR NEUROSCIENCE, 1997, vol.9, p.207-219. Березин И.В., Мартинек К. Основы физической химии ферментативного катализа. - М., 1977. *

Also Published As

Publication number Publication date
JP4920675B2 (ja) 2012-04-18
EP1868989A2 (en) 2007-12-26
KR20070116932A (ko) 2007-12-11
WO2006103261A9 (en) 2010-05-27
CN101193858A (zh) 2008-06-04
CA2600791A1 (en) 2006-10-05
JP2008538178A (ja) 2008-10-16
WO2006103261A3 (en) 2007-02-22
IL186120A (en) 2012-08-30
AU2006228150A1 (en) 2006-10-05
RU2007139754A (ru) 2009-05-10
WO2006103261A2 (en) 2006-10-05
AU2006228150B2 (en) 2011-09-29
US7897364B2 (en) 2011-03-01
US20090170950A1 (en) 2009-07-02
ZA200707359B (en) 2009-08-26
IL186120A0 (en) 2008-01-20
NO20075461L (no) 2007-11-20
BRPI0609654A2 (pt) 2010-04-20
MX2007011961A (es) 2008-03-14
CN101193858B (zh) 2012-01-04
NZ562796A (en) 2010-02-26

Similar Documents

Publication Publication Date Title
Izumi et al. A metalloprotease–disintegrin, MDC9/meltrin‐γ/ADAM9 and PKCδ are involved in TPA‐induced ectodomain shedding of membrane‐anchored heparin‐binding EGF‐like growth factor
JP2010506871A (ja) 血管新生及び脈管形成のモジュレーターとしてのｒスポンジン
US6521436B1 (en) Nucleic acids encoding aggrecan degrading metallo proteases
Rhee et al. Characterization of human cellular γ-glutamyl hydrolase
IL186120A (en) Method for determining whether a test compound is an inhibitor of neurotrypsin
KR100856360B1 (ko) 절단형 ｄａｎｃｅ, ｄａｎｃｅ 복합체, 및 이들을사용하는 방법
JP2003523723A (ja) ヘルマンスキー−パドラック症候群タンパク質相互作用タンパク質およびその使用の方法
Maruvada et al. Increased transforming growth factor‐α levels in human colon carcinoma cell lines over‐expressing protein kinase C
KR20060136471A (ko) 절단형 ｄａｎｃｅ, ｄａｎｃｅ 복합체, 및 이들을사용하는 방법
JP2002532065A (ja) 哺乳動物サブチリシン／ケキシンアイソエンザイムｓｋｉ−１：独特の切断特異性を有するプロタンパク質コンバーターゼ
CA2350165C (en) Novel serine protease bssp6
US20070004636A1 (en) Method of degrading transcriptional factors of saccharometabolism-associated gene, method for inhibiting the degradation, and agent for inhibiting degradation and degradation inhibitor
US6998245B1 (en) Serine protease BSSP5
HK1119156A (en) Inhibitors of neurotrypsin and determination thereof
CA2348971C (en) Novel serine proteases bssp4
EP1132475B1 (en) Novel serine protease bssp2
KR19990022316A (ko) 형질전환 성장 인자 알파 ｈｉ
CA2616940C (en) Novel serine protease bssp2
JP2004329040A (ja) ポリセラーゼ−ｉ及びその利用
JP2008543273A (ja) Ａｄａｍ−ｔｓプロテアーゼの活性を測定するためのチオペプトリドの使用
JP2004166695A (ja) ＲＡＰＬ・Ｒａｐ１相互作用制御
US20050272040A1 (en) Method for increasing synaptic growth or plasticity
JPWO2002057448A1 (ja) 新規ペプチド及びその活性
JP2004222722A (ja) ヒトａｄａｍｔｓ−１タンパク質、それをコードする遺伝子、医薬組成物、及びヒトａｄａｍｔｓ−１タンパク質の免疫学的分析方法

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20130330